Business
Telo Genomics Appoints Kris Weinberg as Chief Executive Officer
Toronto, Ontario--(Newsfile Corp. - December 12, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Appoints Kris Weinberg as Chief Executive OfficerToronto, Ontario--(Newsfile Corp. - December 12, 2022) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"TELO\") is pleased to announce the appointment of Kris Weinberg as Chief Executive Officer (\"CEO\"), effective today. Telo Genomics' current CEO, Sherif Louis PhD, will assume the position of President & Chief Technology Officer. \"These executive changes are integral to TELO's long term growth strategy,\" said John Meekison, Telo Genomics Board Director & Chair of the Audit Committee. \"Sherif has spear-headed the Company's technology turn-around with the successful development of the Telo multiple myeloma (\"Telo-MM\") tests. Telo-MM is being developed to provide important, actionable information to medical professionals for the treatment of multiple myeloma (\"MM\"), a deadly form of blood cancer. We look forward to working with both Sherif and Kris as the Company progresses the commercialization of Telo-MM, moving from lab to clinic.\" Mr. Weinberg is an accomplished industry veteran and commercial leader with deep, hands-on experience in the field of high value molecular testing, with a focus on the commercialization of innovative oncology technologies. Mr. Weinberg most recently led the commercial activities at Theralink Technologies, where he successfully launched the Theralink Assay for Breast Cancer to physicians and payors nationally in the US. Kris previously held commercial leadership roles at Natera, Guardant Health, Biodesix and Genomic Health; where he was successful in launching innovative cancer tests across multiple platforms. \"I am very pleased to join the Telo Genomics' team and look forward to applying my years of experience on the commercialization side of the diagnostic industry to initiate the launch of the Telo-MM diagnostic test,\" said Mr. Weinberg. \"It is a great time to be joining TELO - this is the inflection point of moving from exciting R&D to commercialization. TeloView technology is strongly supported by scientific and clinical evidence and addresses vital unmet clinical needs in the management of multiple myeloma, particularly for high-risk 'smoldering myeloma' patients.\"In connection with Mr. Weinberg's appointment as CEO, the Company has granted 1,000,000 stock options (the \"Options\") wit...